The DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Metal Drugs and the Anticancer Immune Response
Open accessAbstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Chattopadhyay, S., Dash, S. K., Mahapatra, S. K., Tripathy, S., Ghosh, T., Das, B., Das, D., Pramanik, P., & Roy, S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1085-2 · Cited by 50
RetractedChatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Toxicity of gold nanoparticles (AuNPs): A review
Sani, A., Cao, C., & Cui, D. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100991 · Cited by 454
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
New Designs for Phototherapeutic Transition Metal Complexes
Imberti, C., Zhang, P., Huang, H., & Sadler, P. J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201905171 · Cited by 443
The immune microenvironment in cartilage injury and repair
Li, M., Yin, H., Yan, Z., Li, H., Wu, J., Wang, Y., Wei, F., Tian, G., Ning, C., Li, H., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.12.006 · Cited by 403
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metal Drugs and the Anticancer Immune Response. https://app.cochat.ai/papers/10.1021/acs.chemrev.8b00396
- The paper
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019). Metal Drugs and the Anticancer Immune Response. Chemical Reviews. https://doi.org/10.1021/acs.chemrev.8b00396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.